Tevogen (TVGN) Enterprise Value (2021 - 2026)
Tevogen Bio Holdings' (TVGN) quarterly Enterprise Value came in at -$692305.0 in Q1 2026, up 64.95% YoY from -$419717.7 in Q1 2025, and down 25.33% on a QoQ basis from -$552372.0 in Q4 2025.
Tevogen (TVGN) Enterprise Value (2021 - 2026) Analysis & Trends
Tevogen Bio Holdings (TVGN) has 6 years of Enterprise Value data on file, last reported at -$692305.0 in Q1 2026.
- Quarterly Enterprise Value rose 64.95% year-over-year to -$692305.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$692305.0 (up 64.95% YoY) and the FY2025 annual result came in at -$552372.0, up 56.95% from the prior year.
- Enterprise Value eased to -$692305.0 in Q1 2026, from -$552372.0 in the prior quarter.
- In the past five years, Enterprise Value ranged from a high of -$143047.0 in Q3 2022 to a low of -$5.7 million in Q1 2023.
- A 5-year average of -$1.8 million and a median of -$1.1 million in 2024 frame the typical range for Enterprise Value.
- The widest YoY moves for Enterprise Value: up 80.81% in 2023, down 2350.54% in 2023.
- Tracing TVGN's Enterprise Value over 5 years: stood at -$5.5 million in 2022, then soared by 80.81% to -$1.1 million in 2023, then decreased by 21.91% to -$1.3 million in 2024, then surged by 56.95% to -$552372.0 in 2025, then slipped by 25.33% to -$692305.0 in 2026.
- The last three Enterprise Value figures came in at -$692305.0 (Q1 2026), -$552372.0 (Q4 2025), and -$1.0 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | -5.18 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -5.14 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -5.10 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -3.31 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -18.39 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -1.16 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 2.12 Bn |
| 10 | Tevogen | 25.62 Mn | 25.62 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -692,305.00 |
| Dec 31, 2025 | -552,372.00 |
| Sep 30, 2025 | -1.04 Mn |
| Jun 30, 2025 | -685,229.00 |
| Mar 31, 2025 | -1.97 Mn |
| Dec 31, 2024 | -1.28 Mn |
| Sep 30, 2024 | -2.33 Mn |
| Jun 30, 2024 | -1.14 Mn |
| Mar 31, 2024 | -1.32 Mn |
| Dec 31, 2023 | -1.05 Mn |
| Sep 30, 2023 | -2.61 Mn |
| Jun 30, 2023 | -3.46 Mn |
| Mar 31, 2023 | -5.67 Mn |
| Dec 31, 2022 | -5.48 Mn |
| Sep 30, 2022 | -143,047.00 |
| Jun 30, 2022 | -185,645.00 |
| Mar 31, 2022 | -231,546.00 |
| Dec 31, 2021 | -344,581.00 |